This site is intended only for healthcare professionals resident in the Republic of Ireland
Approximately 30%-40% of people with migraine are not successfully treated using a triptan, for reasons of insufficient efficacy and/or tolerability
In a review of clinical studies, only 18%-33% of patients achieve sustained freedom from pain, and 20%-34% of patients require rescue medication
Frequent use of medication for the acute treatment of migraine attacks can lead to medication-overuse headache (MOH)
Oral preventive treatments like anticonvulsants and beta-blockers are associated with AEs such as weight gain, fatigue and cognitive issues
In a survey of 372 patients with migraine, more would prefer to take a pill (63.4%) as a preventive treatment than an injection (36.6%).
11% of patients with migraine have a history of cardiovascular events that make them unsuitable for triptans
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Legal Category: S1B
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023